{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:42:42Z","timestamp":1793241762816,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015035","name":"National Foundation of Elites","doi-asserted-by":"publisher","award":["25025"],"award-info":[{"award-number":["25025"]}],"id":[{"id":"10.13039\/501100015035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012155","name":"National Institute for Medical Research Development","doi-asserted-by":"publisher","award":["973,168"],"award-info":[{"award-number":["973,168"]}],"id":[{"id":"10.13039\/501100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jconrel.2024.03.042","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T19:41:28Z","timestamp":1711482088000},"page":"128-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Extracellular vesicles derived from dendritic cells loaded with VEGF-A siRNA and doxorubicin reduce glioma angiogenesis in vitro"],"prefix":"10.1016","volume":"369","author":[{"given":"Parisa","family":"Shamshiripour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrana","family":"Rahnama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Nikoobakht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahideh Farzam","family":"Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali-Reza","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davoud","family":"Ahmadvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.jconrel.2024.03.042_bb0005","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2010.34.1636","article-title":"Phase II study of aflibercept in recurrent malignant glioma: a north American brain tumor consortium study","volume":"29","author":"Groot","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.03.042_bb0010","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1200\/jco.2011.29.15_suppl.2043","article-title":"Phase I study of aflibercept (VEGF trap) and temozolomide in newly diagnosed, high-grade glioma","volume":"29.15_suppl","author":"De Groot","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.03.042_bb0015","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11060-016-2357-9","article-title":"Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas","volume":"132","author":"Nayak","year":"2017","journal-title":"J. Neuro-Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.03.042_bb0020","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11060-016-2092-2","article-title":"Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma","volume":"128","author":"Duerinck","year":"2016","journal-title":"J. Neuro-Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.03.042_bb0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11060-017-2629-z","article-title":"Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma","volume":"136","author":"Duerinck","year":"2018","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jconrel.2024.03.042_bb0030","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/jitc-2020-001146","article-title":"Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)","volume":"8","author":"Awada","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.jconrel.2024.03.042_bb0035","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cncr.29798","article-title":"Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas","volume":"122","author":"Schiff","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.jconrel.2024.03.042_bb0040","series-title":"A Phase I\/II Study Of Lenvatinib (LEN) Plus Everolimus (EVE) in Recurrent And Refractory Pediatric Solid Tumors, Including CNS Tumors","author":"Cruz","year":"2020"},{"issue":"5","key":"10.1016\/j.jconrel.2024.03.042_bb0045","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/1078-0432.CCR-07-4544","article-title":"Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide","volume":"14","author":"Zhou","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.jconrel.2024.03.042_bb0050","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/neuonc\/nos158","article-title":"Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype","volume":"14","author":"Piao","year":"2012","journal-title":"Neuro-oncology."},{"issue":"5","key":"10.1016\/j.jconrel.2024.03.042_bb0055","first-page":"4185","article-title":"Low dose of doxorubicin potentiates the effect of temozolomide in glioblastoma cells","volume":"55","author":"Villodre","year":"2018","journal-title":"Mol. Neurobiol."},{"issue":"3","key":"10.1016\/j.jconrel.2024.03.042_bb0060","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1134\/S1819712418030030","article-title":"Exosome drug delivery through the blood\u2013brain barrier: experimental approaches and potential applications","volume":"12","author":"Druzhkova","year":"2018","journal-title":"Neurochem. J."},{"key":"10.1016\/j.jconrel.2024.03.042_bb0065","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jconrel.2018.08.028","article-title":"Sequential delivery of VEGF siRNA and paclitaxel for PVN destruction, anti-angiogenesis, and tumor cell apoptosis procedurally via a multi-functional polymer micelle","volume":"287","author":"Yang","year":"2018","journal-title":"J. Control. Release"},{"issue":"11","key":"10.1016\/j.jconrel.2024.03.042_bb0070","doi-asserted-by":"crossref","first-page":"9402","DOI":"10.1021\/acsami.6b16689","article-title":"Highly efficient and safe delivery of VEGF siRNA by bioreducible fluorinated peptide dendrimers for cancer therapy","volume":"9","author":"Cai","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"8","key":"10.1016\/j.jconrel.2024.03.042_bb0075","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99263","article-title":"Generation and testing of clinical-grade exosomes for pancreatic cancer","volume":"3","author":"Mendt","year":"2018","journal-title":"JCI Insight"},{"issue":"12","key":"10.1016\/j.jconrel.2024.03.042_bb0080","doi-asserted-by":"crossref","first-page":"E1433","DOI":"10.1073\/pnas.1418401112","article-title":"Differential fates of biomolecules delivered to target cells via extracellular vesicles","volume":"112","author":"Kanada","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"20","key":"10.1016\/j.jconrel.2024.03.042_bb0085","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1073\/pnas.0600148103","article-title":"siRNA in human cells selectively localizes to target RNA sites","volume":"103","author":"Berezhna","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"12","key":"10.1016\/j.jconrel.2024.03.042_bb0090","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1007\/s00018-019-03071-y","article-title":"Extracellular vesicle isolation methods: rising impact of size-exclusion chromatography","volume":"76","author":"Mongui\u00f3-Tortajada","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.jconrel.2024.03.042_bb0095","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jconrel.2016.10.008","article-title":"Functional exosome-mimic for delivery of siRNA to cancer: in vitro and in vivo evaluation","volume":"243","author":"Yang","year":"2016","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2024.03.042_bb0100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jconrel.2013.08.014","article-title":"Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles","volume":"172","author":"Kooijmans Sander A.A.","year":"2013","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.jconrel.2024.03.042_bb0105","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.it.2006.10.004","article-title":"Angiopoietins: a link between angiogenesis and inflammation","volume":"27","author":"Fiedler","year":"2006","journal-title":"Trends Immunol."},{"issue":"2","key":"10.1016\/j.jconrel.2024.03.042_bb0110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jconrel.2008.03.008","article-title":"Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer","volume":"129","author":"Kim","year":"2008","journal-title":"J. Control. Release"},{"issue":"15","key":"10.1016\/j.jconrel.2024.03.042_bb0115","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.7150\/thno.34314","article-title":"Development of a biocompatible copolymer nanocomplex to deliver VEGF siRNA for triple negative breast cancer","volume":"9","author":"Zhao","year":"2019","journal-title":"Theranostics"},{"issue":"18","key":"10.1016\/j.jconrel.2024.03.042_bb0120","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1016\/j.biomaterials.2014.03.012","article-title":"Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core\u2013shell nanoparticles","volume":"35","author":"Feng","year":"2014","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.jconrel.2024.03.042_bb0125","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jconrel.2012.05.005","article-title":"Pancreatic cancer therapy by systemic administration of VEGF siRNA contained in calcium phosphate\/charge-conversional polymer hybrid nanoparticles","volume":"161","author":"Pittella","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.03.042_bb0130","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.biomaterials.2016.01.068","article-title":"A theranostic micelleplex co-delivering SN-38 and VEGF siRNA for colorectal cancer therapy","volume":"86","author":"Lee","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.03.042_bb0135","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.biomaterials.2018.09.017","article-title":"Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells","volume":"185","author":"Song","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.03.042_bb0140","first-page":"2579","article-title":"Highly effective antiangiogenesis via magnetic mesoporous silica-based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapy","volume":"10","author":"Chen","year":"2015","journal-title":"Int. J. Nanomedicine"},{"issue":"20","key":"10.1016\/j.jconrel.2024.03.042_bb0145","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.7150\/thno.32416","article-title":"Co-delivery of VEGF siRNA and etoposide for enhanced anti-angiogenesis and anti-proliferation effect via multi-functional nanoparticles for orthotopic non-small cell lung cancer treatment","volume":"9","author":"Li","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2024.03.042_bb0150","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jconrel.2015.08.032","article-title":"Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo","volume":"220","author":"Lee","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.03.042_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2014.03.025","article-title":"Ultrasound-assisted siRNA delivery via arginine-grafted bioreducible polymer and microbubbles targeting VEGF for ovarian cancer treatment","volume":"183","author":"Florinas","year":"2014","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2024.03.042_bb0160","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.addr.2012.07.002","article-title":"Exosomes are endogenous nanoparticles that can deliver biological information between cells","volume":"65","author":"Sun","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2024.03.042_bb0165","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.addr.2012.06.011","article-title":"Exosomes as nucleic acid nanocarriers","volume":"65","author":"van den Boorn","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2024.03.042_bb0170","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.addr.2012.08.008","article-title":"Exosomes for targeted siRNA delivery across biological barriers","volume":"65","author":"Andaloussi","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.03.042_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2021.105173","article-title":"Intranasal delivery of exosomes from human adipose derived stem cells at forty-eight hours post injury reduces motor and cognitive impairments following traumatic brain injury","volume":"150","author":"Moss","year":"2021","journal-title":"Neurochem. Int."},{"issue":"19","key":"10.1016\/j.jconrel.2024.03.042_bb0180","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.1039\/D2BM00518B","article-title":"High-efficiency brain-targeted intranasal delivery of BDNF mediated by engineered exosomes to promote remyelination","volume":"10","author":"Zhai","year":"2022","journal-title":"Biomater. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2024.03.042_bb0185","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1021\/acsnano.1c08473","article-title":"Intranasal administration of self-oriented nanocarriers based on therapeutic exosomes for synergistic treatment of Parkinson's disease","volume":"16","author":"Peng","year":"2022","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.jconrel.2024.03.042_bb0190","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3390\/brainsci13040639","article-title":"Intranasal delivery of gene-edited microglial exosomes improves neurological outcomes after intracerebral hemorrhage by regulating Neuroinflammation","volume":"13","author":"Guo","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.jconrel.2024.03.042_bb0195","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s12195-016-0458-3","article-title":"Elucidation of exosome migration across the blood\u2013brain barrier model in vitro","volume":"9","author":"Chen","year":"2016","journal-title":"Cell. Mol. Bioeng."},{"issue":"9","key":"10.1016\/j.jconrel.2024.03.042_bb0200","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4155\/tde.11.83","article-title":"Exosomes and the blood\u2013brain barrier: implications for neurological diseases","volume":"2","author":"Wood","year":"2011","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2024.03.042_bb0205","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jconrel.2022.08.002","article-title":"Overcoming the blood-brain barrier: exosomes as theranostic nanocarriers for precision neuroimaging","volume":"349","author":"Li","year":"2022","journal-title":"J. Control. Release"},{"issue":"11","key":"10.1016\/j.jconrel.2024.03.042_bb0210","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/neuonc\/nos158","article-title":"Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype","volume":"14","author":"Piao","year":"2012","journal-title":"Neuro-oncology"},{"issue":"14","key":"10.1016\/j.jconrel.2024.03.042_bb0215","doi-asserted-by":"crossref","first-page":"11882","DOI":"10.18632\/oncotarget.3592","article-title":"Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy","volume":"6","author":"Xu","year":"2015","journal-title":"Oncotarget"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924001950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924001950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T01:56:29Z","timestamp":1728525389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924001950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":43,"alternative-id":["S0168365924001950"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.03.042","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extracellular vesicles derived from dendritic cells loaded with VEGF-A siRNA and doxorubicin reduce glioma angiogenesis in vitro","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.03.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}